Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totaling 77,600 shares, a drop of 37.2% from the August 31st total of 123,500 shares. Based on an average daily volume of 690,300 shares, the short-interest ratio is currently 0.1 days. Approximately 5.2% of the shares of the stock are sold short. Approximately 5.2% of the shares of the stock are sold short. Based on an average daily volume of 690,300 shares, the short-interest ratio is currently 0.1 days.

Avalon GloboCare Price Performance

Avalon GloboCare stock opened at $2.24 on Monday. The stock has a market capitalization of $8.59 million, a P/E ratio of -0.11 and a beta of 0.03. Avalon GloboCare has a 12-month low of $1.87 and a 12-month high of $11.66. The firm’s 50-day moving average is $2.33 and its two-hundred day moving average is $3.11.

Avalon GloboCare (NASDAQ:ALBT) last announced its earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share (EPS) for the quarter. The company had revenue of $0.35 million for the quarter.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ALBT shares. Wall Street Zen lowered Avalon GloboCare to a “strong sell” rating in a report on Saturday, September 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Avalon GloboCare presently has a consensus rating of “Sell”.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.